302 related articles for article (PubMed ID: 8790398)
41. The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules.
Wu S; Gorski J
Mol Immunol; 1996; 33(4-5):371-7. PubMed ID: 8676888
[TBL] [Abstract][Full Text] [Related]
42. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
[TBL] [Abstract][Full Text] [Related]
43. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent.
Stebbins CC; Loss GE; Elias CG; Chervonsky A; Sant AJ
J Exp Med; 1995 Jan; 181(1):223-34. PubMed ID: 7807005
[TBL] [Abstract][Full Text] [Related]
44. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands.
Muntasell A; Carrascal M; Alvarez I; Serradell L; van Veelen P; Verreck FA; Koning F; Abian J; Jaraquemada D
J Immunol; 2004 Jul; 173(2):1085-93. PubMed ID: 15240697
[TBL] [Abstract][Full Text] [Related]
45. DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms.
Rinderknecht CH; Roh S; Pashine A; Belmares MP; Patil NS; Lu N; Truong P; Hou T; Macaubas C; Yoon T; Wang N; Busch R; Mellins ED
Immunology; 2010 Sep; 131(1):18-32. PubMed ID: 20408893
[TBL] [Abstract][Full Text] [Related]
46. Complexes of two cohorts of CLIP peptides and HLA-DQ2 of the autoimmune DR3-DQ2 haplotype are poor substrates for HLA-DM.
Fallang LE; Roh S; Holm A; Bergseng E; Yoon T; Fleckenstein B; Bandyopadhyay A; Mellins ED; Sollid LM
J Immunol; 2008 Oct; 181(8):5451-5461. PubMed ID: 18832702
[TBL] [Abstract][Full Text] [Related]
47. Peptidomic analysis of type 1 diabetes associated HLA-DQ molecules and the impact of HLA-DM on peptide repertoire editing.
Zhou Z; Reyes-Vargas E; Escobar H; Chang KY; Barker AP; Rockwood AL; Delgado JC; He X; Jensen PE
Eur J Immunol; 2017 Feb; 47(2):314-326. PubMed ID: 27861808
[TBL] [Abstract][Full Text] [Related]
48. HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes.
Narayan K; Chou CL; Kim A; Hartman IZ; Dalai S; Khoruzhenko S; Sadegh-Nasseri S
Nat Immunol; 2007 Jan; 8(1):92-100. PubMed ID: 17143275
[TBL] [Abstract][Full Text] [Related]
49. HLA-DR-restricted presentation of purified myelin basic protein is independent of intracellular processing.
Vergelli M; Pinet V; Vogt AB; Kalbus M; Malnati M; Riccio P; Long EO; Martin R
Eur J Immunol; 1997 Apr; 27(4):941-51. PubMed ID: 9130648
[TBL] [Abstract][Full Text] [Related]
50. Trafficking of major histocompatibility complex class II molecules through intracellular compartments containing HLA-DM.
Robbins NF; Hammond C; Denzin LK; Pan M; Cresswell P
Hum Immunol; 1996 Jan; 45(1):13-23. PubMed ID: 8655355
[TBL] [Abstract][Full Text] [Related]
51. Release of DR molecules from complexes with invariant chain through the formation of a C-terminal 25 kDa invariant chain fragment.
Demotz S; Danieli C
Mol Immunol; 1993 Dec; 30(18):1623-32. PubMed ID: 8272076
[TBL] [Abstract][Full Text] [Related]
52. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.
Antohe I; Tanasa MP; Dăscălescu A; Dănăilă C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Cianga P
Immunobiology; 2021 Jan; 226(1):152049. PubMed ID: 33352400
[TBL] [Abstract][Full Text] [Related]
53. The role of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing and presentation.
Alfonso C; Liljedahl M; Winqvist O; Surh CD; Peterson PA; Fung-Leung WP; Karlsson L
Immunol Rev; 1999 Dec; 172():255-66. PubMed ID: 10631951
[TBL] [Abstract][Full Text] [Related]
54. Structural insights into human MHC-II association with invariant chain.
Wang N; Waghray D; Caveney NA; Jude KM; Garcia KC
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2403031121. PubMed ID: 38687785
[TBL] [Abstract][Full Text] [Related]
55. Human germinal center B cells differ from naive and memory B cells by their aggregated MHC class II-rich compartments lacking HLA-DO.
Chalouni C; Banchereau J; Vogt AB; Pascual V; Davoust J
Int Immunol; 2003 Apr; 15(4):457-66. PubMed ID: 12663675
[TBL] [Abstract][Full Text] [Related]
56. The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules.
Kropshofer H; Hämmerling GJ; Vogt AB
Immunol Rev; 1999 Dec; 172():267-78. PubMed ID: 10631952
[TBL] [Abstract][Full Text] [Related]
57. Identification of the lateral interaction surfaces of human histocompatibility leukocyte antigen (HLA)-DM with HLA-DR1 by formation of tethered complexes that present enhanced HLA-DM catalysis.
Stratikos E; Mosyak L; Zaller DM; Wiley DC
J Exp Med; 2002 Jul; 196(2):173-83. PubMed ID: 12119342
[TBL] [Abstract][Full Text] [Related]
58. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
[TBL] [Abstract][Full Text] [Related]
59. Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium.
Muczynski KA; Cotner T; Anderson SK
Kidney Int; 2001 Feb; 59(2):488-97. PubMed ID: 11168931
[TBL] [Abstract][Full Text] [Related]
60. What to do with HLA-DO/H-2O two decades later?
Welsh R; Song N; Sadegh-Nasseri S
Immunogenetics; 2019 Mar; 71(3):189-196. PubMed ID: 30683973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
